Delivery Order SPE2DR25D2213-SPE2DR26F6DCX
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $81,340.66 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors on December 4, 2025, with completion expected by December 5, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a $18,426.38 delivery order to AmerisourceBergen Drug Corp on December 5, 2025, for REPATHA 140 MG/ML SureClick auto-injector pharmaceutical products, with final delivery due by December 8, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.9 million through December 2026. The contract involves...
- The Defense Logistics Agency awarded a $5,888.04 firm fixed price delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with a completion date of May 5, 2025. This non-set-aside competitive award represents a child delivery order issued against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. The product will be...
- The Defense Logistics Agency awarded a $3,471.40 delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for REPATHA 140 mg/ml SureClick auto-injectors, with final delivery scheduled for April 25, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract with the DLA. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical...
- The Defense Logistics Agency awarded a $1,201.32 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injector pharmaceutical product, with an ultimate completion date of August 28, 2025. This non-set-aside, competitively awarded contract reflects firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger prime contract vehicle with DLA. The place of performance is AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $11,808.70 firm fixed-price delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of December 10, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. REPATHA is a prescription medication used to treat high cholesterol, and...
- The Defense Logistics Agency awarded a delivery order valued at $8,826.84 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of September 4, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The pharmaceutical product will...
- The Defense Logistics Agency awarded a $18,738.83 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of December 2, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's broader pharmaceutical supply agreement with the DLA. The place of performance is the company's corporate headquarters in Conshohocken, Pennsylvania. REPATHA (evolocumab) is a PCSK9...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors valued at $1,135.11, with completion scheduled for September 9, 2025. This firm fixed price delivery order represents a competitive award with no set-aside designation and is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX. The product will be delivered to AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a $4,540.44 firm fixed-price delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of September 16, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical supply vehicle running through December 2026. The place of performance is...
- SPE2DR25D2213Indefinite Delivery Contract
- SPE2DR25D2213-SPE2DR26F6DCXDelivery Order
The Defense Logistics Agency awarded a $8,921.19 delivery order (Contract No. 4570334205) to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors on December 19, 2025, with completion scheduled for December 22, 2025. This firm fixed-price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle active through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical distributor. This delivery order supports the Defense Health Agency's medical supply needs through AmerisourceBergen's comprehensive pharmaceutical distribution network. REPATHA (evolocumab) is a PCSK9 inhibitor indicated for cardiovascular disease management and represents the specialized, high-value medications that characterize the company's federal contract portfolio. AmerisourceBergen's DLA relationship demonstrates its critical role in supporting military and veteran healthcare systems through competitively awarded contracts spanning multiple therapeutic domains, from specialty cardiovascular medications to vaccines and medical devices, reinforcing the company's position as a strategic vendor for federal medical procurement.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.9k | 12/18/25 |